Reviral's series A provides runway to move RSV candidate into the clinic
LONDON – UK start-up company Reviral Ltd. has attracted one of the global stars of nucleoside chemistry and antiviral drugs to its board, as it prepares the ground for a series A later this year to raise £4 million to £5 million (US$6.8 million to US$8.5 million).
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST